Good morning, everyone. Welcome to the earnings call of the third quarter of 2026 of Rede D'Or. We have here today Paulo Moll, the President, Rodrigo Gavina, CEO of hospitals, Otávio Lazcano, VP of Investor Relations, and Raquel Reis, CEO of Health and Dental. We inform you that the event should last one hour, and the recording will be available at the IR website of the company.
Thereafter, we are going to start with a Q&A session, and before we continue, we would like to state that any statements that are done during the conference regarding the business perspective, projections, and financial goals are based on beliefs and information that is currently available.
Forward-looking statements are not a guarantee on performance. They involve uncertainties, and these may or may not occur. Investors should understand that general economic conditions and industry conditions may affect the performance of the company and may lead to results materially different. Now the floor to Mr. Paulo Moll. He will start. The floor is yours.
Good morning, everyone. It is a pleasure to be here. We are very happy with the consistency of the results. Very brief.
Recording in progress.
Of consolidated loss ratio, the drop 77%. Raquel will go over the details. And also this control, the control of the loss ratio, year-on-year, 182,000 lives added. And not counting the administered plans. Now, we have the final phase of works of a few structures. Tatuapé, Glória D'Or, which is important. We delivered phase 2 of expansion of DF Star, and these are the high-demand units, and we are building phase 3 UDI using the flag D'Or at São Luíz D'Or, the new tower. We launched another 80 beds. We are in advanced phase with the works of Ribeirão D'Or.
Also, before giving the floor to Raquel, we were very happy in having the approval for the approval of medicine, the Instituto D'Or, 100 places, infrastructure in Rio de Janeiro, where we have a building built by the state of Illinois, and it was previously a university, so it had adaptations so we can have our medical school. While research and teaching will continue to support us, and we will have an assistance with Rede D'Or. With that, I will give the floor to Raquel. I will be here for the Q&A. Thank you.
Good morning. Main points of SulAmérica. We close September 6.2 million in dental, growth of 8.9% in 12 months. In the quarter, 164,000 lives added. In health, 3.2 million beneficiaries, and the administered plans, as Paulo said, 7.6. 182,000 net additions, prepayment 70,000 lives, and 43,000 in the second quarter of 2026, another quarter that we reinforce the growth. Dental, 3,000 lives, very important. If we have this number, we have a growth of 14%. The consolidated loss ratio gain of 2 percentage points and 2.6 in the quarter, so we close the third quarter 78%.
As we say, this is an addition of factors, no silver bullet. We have the retainment of clients, selling commercial, renegotiation, fraud, and regionalization, so fighting fraud and intelligent products. We also have another one million lives with the modular products, a strategy for pricing. More assertive and consolidated loss ratio lower, and the strategy for health and care investing in this, in transforming SulAmérica to a healthcare management plan. And we have been demonstrating that for three years. Two lines in the quarter.
Administrative expenses, 3.4% in the third quarter to 4.9% now. This is due to more investment in technology and infrastructure and safety. Also, the directives of Rede D'Or and provisions for contingencies. This is a number for the judicialization of the sector, and when we have an operation that is more for retail, this is natural, and provisioning more conservative. We adopt for a few semesters, nothing that changes our strategy, and we continue with responsible, sustainable growth without a price war. These are the main highlights. I'll give the floor to Gavina.
Thank you, Raquel. Great to be here. Giving a quick overview of the hospitals and starting, and most importantly, thank you to the team. We are happy with the results that were delivered, and this is from the work of leaders, physicians, patients, this partnership that Raquel was talking to, SulAmérica, and the other operators, fundamentally in the quality and safety in assistance. I know that we're dealing with basically several financial results, economic, but we need to highlight that this is a quality deliverable.
We're here to take care of the patient, and they should have an assistance that is ever better. We have to talk about the School of Medicine. We have the School of Medicine complements teaching assistance in a robust way and brings quality for the patient. We can identify the work of everyone to get to the results, everybody on their side marching in to guarantee this. We can see page five, that we have the day patients higher, 0.7% higher than the previous quarter.
If we compare it to previous year, is lower, but last year was an outlier. These were quarters of volume that were seasonal, very high volume. If we compare this, is not fair, and we have a strong movement of growth. The surgery got to 163,000, which is higher than the seasonal previous period. This is medical relations, experience of the patient, focused in quality, and it's important to highlight this, that none of this would be possible without all of this focus. Page six, growth of beds.
We have the new units, and we also have a challenge of growing consistently. We grew 154 total beds, and we grow, and we are stable in operational beds quarter-on-quarter. We grow, but always seeking efficiency. The idea is to grow the beds. We are growing the volumes, but to guarantee safety and robustness in what we deliver. It's not just growing beds. We have very low stoppage rates, and we are always thinking about efficiency. Thank you, and I am available, the word for Otávio.
Well, hello, page seven. The gross revenue and average ticket, BRL 10 billion, BRL 340 billion, third quarter, 10.1% of what was verified in the third quarter. An increase of 11.2%, stability in the number of patients, 4.8% higher to the previous quarter. An increase of the average ticket, 4%, an increase of the patient-days. Center of the page, gross revenue, it's 11.7% higher than the previous year of the first nine months of 2025, an increase of the average ticket of 11%, an increase of 5% of the patient-days. On the right, we have the graphic evolution of the average ticket through the records. Page eight. Oncology.
Company gross revenue, BRL 1.2 billion, an increase of 18%, an increase of 7.7%, and volume 9.8, an increase of 8.5%. The result is 3.4%, an increase on volume, 4.9. Center of the page, in the segment, BRL 3.4 billion, an increase of 21%, checking the same period, FY 2025, an increase of the average ticket and the volume. The same way, on the right, we have the evolution of the average ticket for this segment. Page nine. Costs and expenses. Segment of hospital. Company reported total cost of BRL 6.8 billion, BRL 6.5 billion, an increase of 6.7% year-on-year, 2.6 on the quarter comparison.
Total costs accumulated BRL 9.2 billion, first nine months, an increase of 8.9 as the costs went up in comparison to the revenue. We have an increase of gross margin, 2.3 in the annual comparison, 1.5 in the quarter comparison, and an increase, nine to nine months. On the right, general administrative expenses accumulated BRL 424 million in 2026, an increase of 67% in the year comparison. We have non-recurring events in the records, third quarter of 2025, the reversal for the ISS provision, over BRL 100 million.
When we adjust, we see stability for the relevance of SG&A as the gross revenue between 3.9 and 4.1. To the right, administrative expenses accumulated in the first nine months, BRL 1.2 billion, 31% higher than the previous period. When we adjust to the non-recurring events, we see an increase of 11.4% and lower to what was the revenue for the same time. Page 10. EBITDA, net income. The hospital services, an accounting EBITDA of BRL 6.8 billion, a growth of 4.9%, and when we adjust it for the non-recurring, a growth of 14%, a margin EBITDA of 26%.
Accumulated EBITDA in this year's BRL 6.6 billion, 849, 13.1% higher than the previous fiscal year, this year. The net income adjusted BRL 1.5 billion. To the right, the net income accumulated in the nine months, three point You can see the accumulated EBITDA on the slides. The ROI still above 30% since the end of last year. The ROI adjusted is close to 20% since the fourth quarter of the previous fiscal year. On the data of SulAmérica, net revenue, BRL 8.8 billion, higher than the previous year. On the top right, consolidated loss ratio, as it was communicated, 77%, 2.4 percentage points.
Below health and dental, BRL 2.8 billion, a growth of 8.9% or 7.6% when we see the administered. On the left, below, adjusted EBITDA, BRL 1.1 billion. 5.7% higher than the same period of the fiscal year of 2025. Consolidated EBITDA and adjusted consolidated were BRL 3.1 billion in the third quarter. Page 12, indebtedness to the left, cash equivalents, BRL 47.3 billion, gross debt, BRL 49 billion, and net debt, BRL 22 billion. Leverage, the index, 1.65 when we do conservative reading, and this is for the cash allocation. With the technical provisions, we have a leverage index inferior to 107.
The indebtedness is 5.8, the cost of capital CDI 1.1, and on the right, the schedule for amortization. Cash can face the main debt until 2033 in the premise that the cash generation is zero. Last page, reconciliation of the EBITDA. Information to the left, reported for BRL 8.9 billion, positive variation for working capital. Working capital in Rede D'Or, BRL 359 million. And SulAmérica, we have positive on the right. Other items, BRL 189 million. Rent, BRL 500 million. Taxes and social contribution, BRL 400 million is Rede D'Or, BRL 576 million SulAmérica.
Variation of cash in the financial activities, we have captures of BRL 5 billion, and the amortization, BRL 1 billion. The financial expenses of BRL 2.1 billion, the payment of dividends in terms of overcapital, BRL 1.6 billion, repurchasing of shares, BRL 1.2 billion. The variation of cash related to the investment, negative BRL 1.7 billion.
We have investments in greenfield, brownfields, small expansions, information technology, maintenance. On the opposite, transference of Glória D'Or to JV, BRL 644 million, and BRL 200 million in other items. The cash variation before the social security, BRL 4.7 billion, or after the variation, BRL 4.9 billion. We finished. We are open for Q&A. Thank you.
If you want to ask a question, please raise your hand. First question, Samuel Alves, BTG.
Thank you, Paulo, Raquel, and the directors. Two questions. First, the increase on the expenses of third parties in hospitals and insurance in SulAmérica, which you mentioned in the presentation, technology and infrastructure. Is there any effort for this quarter, or should we look at a threshold for these lines? The second is the worsening in the contingency, which is related to judicialization. Was there a change in criteria? The curve, isn't it more inclined? Thank you.
First question. You have two effects. One is payment of successes in proceeds and some impact in that line. In that line, we also have technology. We have a team that has been important for deliverables and gains of efficiency that we will have more automation, AI. This is happening, and we're working in regards to the revenue. There is balanced behavior, so we will look, we will accelerate, but always trying to find the dilution and with the expectation that these are important structures for the productivity gains.
Hello. First point. Investment in IT. This is an investment middle term. It's pinpoint, but it's not going to be presented in one quarter. It's an investment in infrastructure. You can imagine a company of 130 years, six million clients, it's a complex operation. I want to reinforce that we are investing in the diversification and retail, which brings complexities. It's a dynamic that demands agility, personalization, and operational efficiency. This IT investment is key to allow for the continuation of this operation, making it safer and competitive, bringing a better experience for the client.
In the judicial expenses, same correlation. We see the sector more legal demands, and we got to the last two years selling that is very high. It's natural that we have more judicialization. Nothing changed, no criteria, and this is what we've seen. Readjustments, investment, nothing new, but with a higher volume, because now we have more people being hired.
Next question, Joseph Giordano.
Hello, good morning. Thank you. My question is three points, very quick. First, looking at the environment, macro, how do you see the innovations in the payment in hospitals and providers? How do you see the payments and the inflation, and how do you see the inflation in the sector since we have an exchange rate effect that should start working now?
Second question is for Paulo. The company has a cash generation very good, even with a high CapEx. What do you see in opportunities for growth of M&As, hospitals, medical accessory services? Exploring this oncology vertical, how much do you see in highlight in the quarters? Thank you.
The payments of price, the tickets of hospitals, it is important to say that the tickets of the hospital is growing 10%. There is an effect of mix in there. We lose volume year-on-year in regards to the total in places with a lower ticket, and we grow volume in hospitals of higher ticket. We have an important growth for surgery, which brings a benefit of the ticket and oncology, as you mentioned. Our policy, it is the same that has guided you since the IPO. It has been 10 years, always replenishing something above IPCA. What goes above has these effects of hospital mix and the complexity of procedures and strategy.
Getting us in a positive, favorable position for the more complexity procedures. Before Raquel, talking about SulAmérica. Let me comment the cash generation. It is a good problem. We can debate what can we add in the strategy. We try to bring discipline because we do not want to have a high leverage and do investments with low return rates or opening to things that are not in the strategy. We understand that we do good and we can generate good returns in these verticals of our strategies. We will be open to adding organic events and acquisitions.
Even though the company was built through M&As, they are important in our history. The M&As did not happen over the years, and organic had an important role. We have the expectation, we have an M&A area that has opportunities, and we hope to be more active than in the last four years, considering inorganic. Observing moments in the price of the share that we have repurchased to generate value and excess of cash, even after these organic, inorganic investments, eventually, we will consider the dividends.
Hello. Let me divide it in two parts. One, readjustment for subcontracted parties. More and more the teams that deal with these for the remuneration models, the clinical outcome, we do not see any changes in the format or what we are getting with the negotiation. Inflation, conventional. I need to remember that the ticket derives from the mix of products. We saw that September, we had a migration. Three big clients that were in prepayment, consolidated loss ratio pressured, and they were migrated for our portfolios post-payment.
So they kept in 50,000 lives, and they prejudiced the average ticket evaluation. We try to pass from the client the improvement in the consolidated loss ratio. 29 lives with the four main players comparable. Our number is 11.8% for May and April, and it is a lower number. So the corridor, but we want to pass on that to the client so we can have pricing that is more sustainable, allowing for the client to stay.
Thank you.
Next question, Gustavo Tiseo.
Good morning. Two questions. Medical materials, positive seasonality, but we always think that it might be an OPME, or to give more color, we have a strong result, and maybe this is the sequence, 19.8%, but very strong in the third quarter. Second point, organic expansion. You commented on projects that should open until the end of the year. Can you give us details on what we should expect? The main point is to understand if we look at the operational beds, if there is a barrier when it is 73, and would there be a lock on the expansion?
Otávio, income and revenue, there is nothing extraordinary. Eventually, we said the mix of a quarter might be different from the average of a year, and we will direct you to periods of 12 months. There might be a change of trend with the different quarter. No. The hospitals that I mentioned, we have a brownfield of DF Star. We have the new ICU tower taking the door, and we are talking about these structures, 80 beds. Rede D'Or has a higher potential of 180 beds. There is a phase II, and here we open according to demand.
Your question about operational beds versus total beds, difficult to look at this in a consolidated way. Always case by case. This year, we have lower growth of operational beds than total beds. We are ramping and growing the operational beds in markets such as São Paulo, Rio, Brasília. At the same time, you can close some beds that had an important relations with self-management that was discontinued. This vision is hospital by hospital.
Hospital by hospital that you have closed beds, we are not going to do an expansion until we have demand and visibility of occupation. But simultaneously, we will have another infrastructure that is occupying all the other beds, and we are doing a new tower. This is just one of the parts. There is no rule that you should guide yourself.
Next question, Leandro Bastos, Citi.
"Good morning. Two on our side. Taking these comments of operational beds, the direction of pack per day, we have the discontinuing effect and the impact on the results, but when can you reimagine the reacceleration? If you can talk about the surgery gaining shares. What are the main levers?" Second, Atlântica D'Or, several projects, Rio, São Paulo, going to Minas Gerais. A few things about new regions, new places. What do you see a perspective?
We work to grow every month. Last year was important for the growth pack day, and we have the Northeast, which is not a growth of pack days as we would like. There is a focus in efficiency with the growth of EBITDA and the margins. When we look ahead, we are thinking and challenging to grow pack per day. We are not seeing an unnecessary movement for removal of registration, but that happens. I am not going to promise, but to make clear that we are always going to work for the growth of the company.
We are expanding the hospitals, and in the hospitals, we will always find the alternatives for the growth and re-occupancy of these beds. Atlântica D'Or, I cannot give you color about the strategies or the markets. Whenever there is something new, we will give you the rationale, and we reinforce that this is an important avenue of growth and markets to be analyzed by Atlântica D'Or.
Next question, Goldman Sachs.
"Good morning. Thank you for the presentation. Two questions. First, revenues outside of the bed." I am not talking about oncology, more diagnostics. Do you see this line growing quickly or not than the business? It would be nice to have visibility, and there might be an interference on the counting of tickets because of the channel checks, diagnosis, more country level. I want to understand how that is reflected on the dynamic.
Second point, the contingency on Sula, a technical doubt. When we have the movement, there is an increase of the composition of contingencies, but payment of provisions is stable. How should we interpret this dilution of payment for the contingency composition? This is the scenario for the judicialization, being able to mitigate, and the outputs are better than what you expect.
Let me start with the first question. We try to organize and improve our hospitals to meet the requirements of the patients' admittance or diagnostics. There is growth. There are some hospitals that didn't have the flow organized, and we dedicate a few machines. We can service the patient that already goes to the ambulatory in big numbers. That doesn't have a relevant impact at Rede D'Or, given that the weight of the admittance is high, but the organization of the company, diagnostics, and procedures, colonoscopy, and we see a demand growing.
We try to service these patients' provisions to Otávio.
Miele, 2025, the company changed the provision, more conservative, and more provisions for the demands. Second quarter 2025, provisions are growing higher than the payments. This is conservative issues, demands that will go through the judiciary, and the payments are reality. There is an extra dose of being conservative.
Next, Maurício Cepeda, Morgan Stanley.
Paulo, Raquel, two questions. Hospital mix. Clearly, there was complexity second quarter. You can see more complexity, but even with the higher complexity, the gross margin improved. Our question is, can you comment on what are the aspects of mix that are favorable? What are the procedures, geography, the paying party? Is there an effect of cost that helped you? We can project the trends, which is very relevant.
Second question, expansion profile. Second quarter, trend to complexity. Quarters don't say much, but there is a trend of strong complexity, less dependency on seasonal cost. Does that change your expansion ambition? The geography will be important, more than the expansion where you are. The rhythm might change. Can you comment on the profile of expansion?
Complexity has an impact over the quarters, and we have a part of the ticket that comes from the complexity. What we are adding to the gain of ticket stems from the growth of volume being concentrated in states and hospitals that have a higher ticket. This mix of our hospitals. They are taking the ticket, and of course, it helps in the profitability. When you grow volume and you have a margin of contribution that is higher, then you have the gains of efficiency.
This is a trend, and we will see our growth more concentrated. When you talk about markets, I'm interpreting states. We will see growth concentrated in markets that have this characteristic, and we see a lot of opportunities getting into new cities in these markets. That will have an impact in our strategy and our ambition of growth, adding markets in the states where we are not positioned.
There's going to be an entry in a state where we are not present. So, maybe we want to add our presence in a state that we are not in, but what is going to impact our results is our growth in markets that we are present, cities that we are present, and the opportunities of growing through brownfields or greenfields, or cities in states that deserve reference assets in the same way that we have done to entries in Guarulhos, Alphaville.
We announced we are building in Sorocaba, Taubaté. We have a terrain in Jundiaí. It is a market that we are present, but cities that lack hospitals with our brands. That will have an important weight besides the brownfields where we see the growth of the demand. Thank you for adding two questions.
Next question, Caio Moscardini. Hello.
Hello. Thank you. First question, interest rate, high inflation, how does that change your strategy for capital allocation, and does that affect the schedule of the projects or increase selectiveness if the repurchasing is more attractive than the expansion? Second, complexity and the growth of surgeries robust, very difficult year-on-year. I want to understand how much of this performance is from the attraction of new physicians and the capture of other hospitals and the increase of productivity, how much it comes from the increase of productivity that you have.
Capital allocation is our exercise that is day-to-day. Repurchasing, open program, price of shares open and oscillate, so we have to decide capital allocation every day. Very difficult for us to give up a project because of a scenario of inflation, because these are projects, whether if it is a brownfield or we see the need of expanding or new market, these are projects that we see as strategic, and we do not have to have a growth of market for this project to be viable.
When the market is growing, that helps, but it does not mean that at a moment of stability or reduction of the size of the market that we are going to abandon the projects. This company kept the rhythm of growth between 2014 and 2020 when we left from 51 million to 49. We hope the scenario is positive from 2014 to 2020, but that does not change our decision of investment in these expansions that we mentioned.
About surgical growth, two things. I would not have a percentage. It is the work of each hospital unit to review and identify good professionals that want to be a part and want to prioritize their work and reinforcing our relationship with professionals that are growing alongside us. We had. In a few strategies, you have the clinical body, and there is an increase in others. You have the arrivals of new physicians, oncology. There is a group that is relevant within our structures and that helped in the growth. This investment is very high, the best medical technologies that are more expensive.
Before, we did not have robotics. These are expensive equipment, but this is the way that you can bring professionals that want to have access to this type of technology. The da Vinci robots or orthopedics or transplant. We have high complexity, and you have other complexity procedures when you are enabled to treat these complex cases. In general, that's it.
If you can limit to one question. Next question, Felipe Amancio, Itaú BBA.
The consolidated loss ratio, the cost for the beneficiary is healthy. Even with the ticket low, do you see this cost as the mix of the company? Just so I can understand if the ticket has gained space in the portfolio and it has less utilization. Second question, cost of staff. [inaudible], you have technology team, but the people that pass on the cost have a dilution. I want to understand if there is a reclassification in this cost.
Hello, Felipe. About the consolidated loss ratio derives on a lot of things. Everything that I mentioned, the mix of products have an impact. It derives on the impact of co-participation, reimbursement, if there is. The modular products, that modular is for reimbursement. Plans for the base of the pyramid is reimbursement for emergency consultation. It doesn't have for therapy or exams. As we go up on the pyramid, the reimbursement is modulated, and it looks to the population that we service, but that has a reduction of value.
All of the issues that we have, the adjustment of products, all of that derives in the consolidated loss ratio. We see the number 71%, very positive. It's comforting. Shareholder is demanding, but we always try to pass that on to the client. So we have prices that are competitive for the acquisition of new clients and the negotiation of readjustments. In the potential, we will keep the mantra of keep all the fish in the aquarium, keeping the company's client with us, even though there is a decrease of lives. So when they grow, they will be around here.
That's a strategy in the period that Paulo mentioned in 2014, 2020, and it's our strategy. Customer in-house. Second question, cost of staff. Combination of good cost and management, and we dealt with volume, nothing abnormal.
Next, Flavio Yoshida.
One question related to the macro and 2027 on the other optic. If you have a perspective of accelerating the expansion and the participation of the market taking on the fragility of smaller players. So, do you see this moment of challenging macro as a good opportunity for consolidation? The second question is SulAmérica. We've seen the growth of lives. I want to know if there is a new product. We have the entry of [inaudible] . How do you see this region with more care?
You're right. Moments of crisis, if we look at our history, when we were more capitalized than the average, we kept the investments, we gained more market share. Nobody wants a crisis. We want a macroeconomic scenario that we hope the country can navigate with stability, but we are always ready for any scenario. The fact that we have this robustness of keeping the investments regardless of the macroeconomic scenario brings this economic advantage and gaining more market share. If a crisis appears, nothing changes since January.
The strategy that we see are bearing the fruits of that virtual cycle, good management of the company, and the point before. We try to pass on to prices everything that we can do better in the consolidated loss ratio. There is an improvement, but there is a pass of the final client and the renegotiation of adjustment and the acquisition of new clients. Another point is that the company breathes commercial. 5,000 people for maintenance, for satisfaction of the clients. This is an obsession for us, and this is translated into this.
Thank you.
Next, Thiago Marmo, Safra.
Good morning. Two questions. One is structural. We see the consolidated loss ratio improving in SulAmérica for a few quarters. Co-participation, reimbursement. I believe that a great deal of the sector is doing initiatives that are similar. On the other side, looking at the hospitals and looking at the sector of an up, we see the occupancy level worsening, and it is important because you can see both sides of the game. How do you see the frequency of use per beneficiary? Do you see a change, structural? Can that change the way that you think about occupancy? Intangible, that is a more Can you tell us what is the intangible and what is the new recurring level?
Here is a great deal of the responses that you seek. On our side, no structural changes. The improvement in the consolidated loss ratio doesn't bring a change in frequency. On the other hand, we are investing in empowering the beneficiary. We have the closing of October, and we have utilizations that wouldn't happen at that moment.
We have vouchers to do ultrasounds at the Pink October campaign without any need to get a medical request because we understood that this is an age of risk. They didn't do preventive, and we are doing the provocation, so that is done. I inserted in the lines of care. A cost that is lower. Structurally, I don't see a lot of oscillation in per capita.
Speaking of the occupancy of the hospitals, our opinion is those that didn't do homework for electives, they have an occupancy problem because there is no expressive demand of respiratory syndromes. Pediatrics was not near a volume. This capacity of compensating an emergency, bringing the volume of elective surgeries is fundamental for the delivery of results. When you can combine both things, good volume of surgeries with a good volume of emergencies, you get to occupancies that are high, which is the third quarter of last year.
Difficult to predict the future. We try to be efficient in what we have control, and the team could deliver the results even in a market that had operations that were lower. You mentioned the intangible and depreciation and demonstration of the books. The contracts that are due, new contracts are signed, there is nothing special in this line. The threshold is a base for you to project the results of the company.
Thank you.
Q&A session is done. Let's close the session.
Thank you very much to the team of Rede D'Or and SulAmérica. We are having a positive year, and I am happy to be close to the 50 years of Rede D'Or that started as Cardiolab in 1977. Next year, we are 50, and this is an important moment.
Our strength is of the team and the strength of this team, whether if it is from the leadership, high management, and mainly our team of the hospitals, SulAmérica, of our physicians. I think that we are in a period that is very gratifying. We can follow our purpose of offering medicine to more Brazilians, and society can count on us. We will continue to invest in this country, taking our standard to more Brazilians. Thank you. We should be ready. Should be closed by soon. We're going to close the earnings call.